John Wittenborn, Joanne Brady, Michelle Dougherty, David Rein – 30 March 2017 – We forecast the health and budgetary impact of hepatitis C (HCV) treatment on the Medicare program based on currently observed rates of treatment among Medicare and non‐Medicare patients and identify the impact of higher rates of treatment among non‐Medicare populations.
Alessandro Soria, Massimiliano Fabbiani, Giuseppe Lapadula, Andrea Gori – 30 March 2017
German Soriano, Jasmohan S. Bajaj – 30 March 2017
Mitra K. Nadim, Jody C. Olson – 30 March 2017
Lara Dakhoul, Naga Chalasani – 30 March 2017
Pin Liu, Mengmeng Ge, Junjie Hu, Xiaolei Li, Li Che, Kun Sun, Lili Cheng, Yuedong Huang, Maria G. Pilo, Antonio Cigliano, Giovanni M. Pes, Rosa M. Pascale, Stefania Brozzetti, Gianpaolo Vidili, Alberto Porcu, Antonio Cossu, Giuseppe Palmieri, Maria C. Sini, Silvia Ribback, Frank Dombrowski, Junyan Tao, Diego F. Calvisi, Ligong Chen, Xin Chen – 30 March 2017 – Amplification and/or activation of the c‐Myc proto‐oncogene is one of the leading genetic events along hepatocarcinogenesis.
Pramod Kumar, Sunil Taneja, Virendra Singh – 30 March 2017
Alessandro Soria, Massimiliano Fabbiani, Giuseppe Lapadula, Andrea Gori – 30 March 2017
Young‐Suk Lim, Yung Sang Lee, Geum‐Youn Gwak, Kwan Soo Byun, Yoon Jun Kim, Jonggi Choi, Jihyun An, Han Chu Lee, Byung Chul Yoo, So Young Kwon – 30 March 2017 – Combination therapy has been recommended for the treatment of patients harboring multiple drug‐resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir.